New drug targets root cause of rare nerve disease in early trial
NCT ID NCT07573332
First seen May 17, 2026 · Last updated May 17, 2026
Summary
This early-phase study tests whether the investigational drug CC-97540 is safe and tolerable in up to 5 adults with a specific type of neuromyelitis optica (NMOSD). Participants have stable disease on standard therapy and will continue their current treatment while receiving the study drug. The main goal is to check for serious side effects and see if the drug can eliminate harmful antibodies from the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AQP4+ NMOSD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern
Dallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.